NCT06066905 A Study of Chidamide With AZA in MRD Positive AML After Transplant
| NCT ID | NCT06066905 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Guangdong Provincial People's Hospital |
| Condition | AML, Adult |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2023-10-26 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2023-10-26 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
acute myeloid leukemia (AML) is a malignant tumor of the hematopoietic system with high heterogeneity in cytogenetics and molecular biology.Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is still the primary treatment option for patients with AML and the most effective method for radical treatment of AML.Despite considerable progress in allo-HSCT over the past decade, 30%-40% of patients still relapse, and post-transplant relapse remains the leading cause of death in patients with AML.
Eligibility Criteria
Inclusion Criteria: 1. Patients diagnosed with AML (diagnostic criteria refer to WHO2016 criteria, except M3) can detect small residual lesions (MRD) positive after allogeneic hematopoietic stem cell transplantation (allo-HSCT); 2. ≥18 years old; 3. ECOG≤3; 4. lifespan≥3 months; 5. Take contraceptive measures; 6. Sign informed consent. Exclusion Criteria: 1. Allergic to the study drug; 2. A gastrointestinal condition that prevents oral medication; 3. active infection; 4. Dysfunction of vital organs; 5. other malignancies; 6. HIV infection; 7. HBV or HCV; 8. The QT interval is prolonged; 9. Pregnant or lactating women; 10. Is participating in other clinical studies; 11. The researchers did not consider it appropriate to participate in this study.
Contact & Investigator
WENG jian yu, M.D.
PRINCIPAL INVESTIGATOR
Department of Hematology, Guangdong Provincial People's Hospital
Frequently Asked Questions
Who can join the NCT06066905 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying AML, Adult. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06066905 currently recruiting?
Yes, NCT06066905 is actively recruiting participants. Contact the research team at wengjianyu1969@163.com for enrollment information.
Where is the NCT06066905 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT06066905 clinical trial?
NCT06066905 is sponsored by Guangdong Provincial People's Hospital. The principal investigator is WENG jian yu, M.D. at Department of Hematology, Guangdong Provincial People's Hospital. The trial plans to enroll 60 participants.